STAT3 and Hepatic fibrosis: These fibrinogens may foster HSCs activation by binding to integrin αvβ3/5 on HSCs’ membranes, suggesting the POFUT1/NOTCH/HES1/STAT3/fibrinogen axis as a novel therapeutic strategy of liver fibrosis (He et al., 2024).